1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
MedGen, Inc.

MedGen, Inc.

MDIN
MedGen, Inc.US flagOther OTC
0.00
USD
- -
- -
90,309.00Market Cap
MedGen, Inc.
MDIN
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2000
2001
2002
2003
2004
2005
2006
2007
2008
TTM
FRC
- -
- -
- -
- -
- -
- -
20.59
18.77
- -
1.63
Revenue per Share
- -
- -
- -
- -
- -
- -
-601.04
-164.41
- -
-8,898.3
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
-217.54
-18.87
- -
-2.59
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
-2,591.76
-515.82
- -
-8,970.45
Book Value per Share
- -
- -
- -
- -
- -
- -
-520.73
-218.15
- -
-8,926.89
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
Basic Weighted Avg Shares
2
2
4
2
1
1
- -
2
1
1
Sales/Revenue/Turnover
-11.68
-66
-28.46
-19.46
-868.35
-1,109.12
-1,111.62
-150.2
-159.32
-159.3
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-2
-1
-1
-9
-12
-8
-15
-6,057
-6,057
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-11.93
-66.57
-37.41
-25.7
-879.24
-1,522.81
-2,919.76
-876.17
-546,928.31
-546,928.31
Profit Margin (%)
- -
- -
- -
- -
- -
-2
- -
-21
-6,077
-6,077
Working Capital
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
-1
- -
-2
-7
-21
-6,077
-6,077
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
51.14
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
ST Debt
6
- -
6
LT Borrowings
- -
6
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
2
23
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
30
1
6,077
Payables & Accruals
1
1
1
ST Debt
6
- -
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
5,662.08%
29,512.41%
Free Cash Flow
- -
62.17%
-0.52%
Net Income, GAAP
- -
8,120.94%
39,064.18%
Sales/Revenue/Turnover
- -
74.09%
-37.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
1
- -
2
2008
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-694.48
-1,977.59
-71.03
- -
-601.04
2007
-25.25
-25.71
-33.72
- -
-164.41
2008
-59.95
19.66
-595.87
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
Similar Companies
TMT (India) Ltd. (TMTIND-B1.BO)
Shukra Pharmaceuticals Limited (SHUKRAPHAR.BO)
Oxygenta Pharmaceutical Ltd. (OXYGENTAPH.BO)
Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
Health X Platform Limited (SASTASUNDR.BO)
Kiaro Holdings Corp. (KO.V)
Business
MedGen, Inc. is a Canadian-based healthcare technology company specializing in the commercialization and investment of medical technologies and life sciences innovations. The company operates through multiple segments including development and commercialization of advanced medical devices, biotechnology products, and pharmaceutical technologies. Its core products and services encompass materials testing, nondestructive testing, failure analysis, test specimen machining, dimensional inspection, toxicology, biocompatibility testing, microbiology, chemistry, and special projects, catering primarily to pharmaceutical and chemical industries. MedGen offers FDA-registered, GLP-compliant, ISO 9001, and ISO 17025 certified laboratory services designed to support product quality, safety, and regulatory compliance. The company targets pharmaceutical, chemical, biotech, and medical device manufacturers, operating predominantly in North America with extended reach through strategic partnerships. Recent major developments for MedGen include a focus on expanding its one-stop-shop integrated solutions for pharmaceutical and chemical companies, broadening its product range via reliable partnerships, and enhancements in technology platforms. The company has notably engaged in a reverse merger transaction acquiring 9430075 Canada Ltd. in 2020, positioning itself towards rapid growth and diversification. Operationally, MedGen is reinforcing its laboratory service offerings by adding advanced analytical capabilities such as SEM/EDS analysis for materials testing and failure analysis. It is also actively improving its share structure and corporate governance framework while driving strategic initiatives aligned with sustainable health technology advancements. These efforts reflect MedGen’s strategic shift towards comprehensive service integration and technology commercialization to elevate its market positioning in the health care technology sector. Founded in 2015 and headquartered in Canada, MedGen continues to leverage scientific and technological innovations to enhance health outcomes and industrial compliance.